Skip to main content

Utility of Drug Levels and Anti-Drug Antibodies When Starting TNF inhibitors

A prospective cohort of 331 patients tested for anti-adalimumab (n=160) and anti-etanercept (n-171) antibodies after initiation of their TNF inhibitor therapy. At 3 months, ADAbs and low adalimumab drug levels were significant predictors of lack of 12 month EULAR response (area under curve 0.71, 95% CI 0.57-0.85). Etanercept levels were not significantly associated with 12 month EULAR response after adjustment. BMI ≥ 30 and poor adherence were associated with lower drug levels.

ADD THE FIRST COMMENT

If you are a health practitioner, you may to comment.

Due to the nature of these comment forums, only health practitioners are allowed to comment at this time.

Disclosures
The author has no conflicts of interest to disclose related to this subject